
May-2023

Axonal Myeloneuropathy



Daniel Neri HMC - Dr. M. F. Khan

Topics to review

Myeloneuropathy

- Definition

- Clinical symptoms

- Disorders

- Conclusion

Definition



Myeloneuropathy: a disorder that affects both the spinal cord and peripheral nerves.

Classification:

- Metabolic: Vitamin B12, B9 deficiency, E deficiency, copper deficiency
- Infectious: HIV, HTLV
- Hereditary disorders: Adrenomyeloneuropathy
- Drugs: Nitrous oxide, Clioquinol
- Paraneoplasic: Breast cancer, Lymphomas
- Inflammatory: Sjögren, Sarcoidosis





Approach to a Case of Myeloneuropathy

- 1. Clinical recognition of myeloneuropathy
- 2. Blood levels

Vitamin B12, folic acid, vitamins A, D, E, and K, iron, and calcium

- 3. MRI of the brain and spinal cord, with contrast
- 4. EMG and NCS -> axonal sensorimotor polyneuropathy.
- 5. Identification of myeloneuropathic patterns: clinical, radiographic, and electrodiagnostic
- 6. Treat the specific cause



CINICAL PATTERNS

SPINAL CORD INVOLVEMENT

- Lhermitte's sign
- Hyperreflexia, Spastic paresis
- Sensory ataxia
- loss vibration and proprioception
- Autonomic dysfunction

PERIPHERAL NERVES INVOLVEMENT


- Distal paresthesia
- Neuropathic pain
- Hyposthesia
- Muscle atrophy

Other etiology-specific symptoms

Causes of Myeloneuropathy

Subacute combined degeneration

- Symmetrical **demyelination** of the spinal cord tracts - insufficient maintenance of myelin



Dorsal column = loss vibration and proprioception, tactile sensation, sensory ataxia (Romberg +)

Lateral columns = Spastic paresis (lateral **corticospinal** tract)

• **Pyramidal signs =** increase deep tendon reflexes, extensor plantar response.

Spinocerebellar tracts and dorsal columns= spinal ataxia

Autonomic dysfuntion = impotence and incontinence, orthostatic hypotension **Neuropsychiatric disease =** reversible dementia, depression, paranoia

Causes: Vitamin B12 \downarrow , Folic acid \downarrow , Vitamin E \downarrow , NO intoxication, Copper \downarrow

Vitamin B12 Deficiency


Etiology


- 1. Decrease intake Malnutrition, restricted diet
- 2. Decrease absorption Pernicious anemia
- 3. Increase requirement Pregnancy

Symptoms

- Subacute combined degeneration of the spinal cord
- Peripheral neuropathy distal paresthesia (earliest sign), pain, hypoesthesia, muscle atrophy
- Vision loss
- Dementia

Dorsal column: early involvement





Megaloblastic anemia:

- Glossitis
- Pallor
- Scleral icterus

Findings

- CBC megaloblastic anemia with increased MCV
- Peripheral blood smears hypersegmented polymorphonuclear leukocytes
- Low serum vitamin B levels confirm the diagnosis
- MRI T2-weighted signal change in the **posterior** and **lateral columns**, enhance with contrast
- EMG axonal peripheral neuropathy

Tx: Cobalamin 1000 mcg/day IM for 5 days, monthly afterward

Neurology recovery may be incomplete, but some improvement over 6-12 months after therapy



Folate deficiency

VS

Vitamin B12 deficiency

Etiology - less common

- Malabsorption
- Medications = methrotrexate,
 phenytoin, PPI, metformin.
- Chronic **alcohol** use

Dx = Elevated homocysteine levels
normal MMA levels


Tx = Folate 1 mg orally 2-3 times per day for several days, followed by 1 mg/day

Etiology - prevalence older adults (5-14%)

- Malabsorption
- Malnutrition
- Pernicious anemia

Dx= Elevated homocysteine levels
Elevated MMA (methylmalonyl Acid)
levels

Tx = Cobalamin 1000 mcg/day IM for 5 days, monthly



Demyelination: impaired Fatty Acid Metabolism, decrease methylation process in the myelin, and increase homocystein levels

Copper deficiency

Rare cause, the mechanism is uncertain. Etiology - Decrease copper absorption


- Bariatric surgery
- Malabsorption
- Zinc overload **OTC products**

Clinical symptoms:

Myelopathy - Subacute combined degeneration Peripheral nerve involvement

Dx - low serum copper and ceruloplasmin levels

MRI of the spine - hyperintense lesions in the posterior column



Treatment Replace copper

- Copper 8 mg/day orally for 1 week, 6 mg/day for one week, 4 mg/day for one week, then 2 mg/day
- improvement is variable; most patients have some residual deficits

Vitamin E deficiency

Rare cause

Etiology

• Fat malabsorption disease: Chronic cholestasis, Pancreatic insufficiency, abetalipoproteinemia,

Clinical

- Ophthalmoplegia
- Retinopathy
- Spinocerebellar syndrome ataxia
- Myeloneuropathy (dorsal columns) = ataxia, ↓ proprioception and vibration sensation
- Peripheral neuropathy

Dx - Low serum vitamin E levels

EMG - axonal, primarily sensory peripheral neuropathy

Treatment

• Vitamin E 200 IU/day–1000 IU/day



*Vitamin E prevents oxidative damage

Nitrious Oxide Myeloneuropathy

Importance - NO one of the more commonly used anesthetic agents worldwide.

Recreational NO use - "whippets"

Physiopathology - alters colbat core of cobalamin, converting it into an inactive, oxidized form.

time onset: immediately to 2 months following NO exposure

Clinical symptoms:

- Myelopathy
- Peripheral neuropathy
- cognitive changes

Tx: cessation of NO and vitamin B12 IM.

Sensory and motor impairment persisted in most patients.



Paraneoplastic myeloneuropathy

Physiopathology - Immune-mediated response triggered by an underlying malignancy (Breast, Lung, Ovaric, Lymphoma)


Clinical symptoms:

- Myelopathy
- Peripheral neuropathy. More predominant
- Other: limbic encephalitis, Lambert-Eaton Myasthenic syndrome

Most common association - **Anti-Hu** - present in 2% (of lung cancer)

Treatment: IV methylprednisolone, IV immunoglobulin

- Molecular Mimicry
- Autoimmune response



Sjögren syndrome

Physiopathology - an autoimmune disorder associated with exocrine gland impairment. Caused by demyelination, myelitis, antineuronal antibodies, antibody-mediated autonomic dysfunction

Clinical symptoms:

- xerophthalmia, xerostomia,
- Myelopathy
- Segmental radiculopathy often precedes the clinical manifestation

Dx: hyperintensity on T2-weighted cervical spinal cord MRI

Tx: IV methylprednisolone, IV immunoglobulin methotrexate, cyclophosphamide, azathioprine, chloroquine, infliximab

Myelopathy Associated with Human T-cell Lymphotropic Virus Type I

HTLV-1 - retrovirus - transmitted sexually, via contaminated needles, and through breastmilk

HTLV-1 -> immunologic response in the <u>CNS</u> -> neurodegeneration

2% of carries develop - Topical spastic paraparesis

- Progressive myelopathy in equatorial countries
- Spasticity, weakness, hyperreflexia, and urinary symptoms
- Addition: uveitis, alveolitis, polymyositis

Tx: supportive



HIV Myeloneuropathy

late stages of HIV infection

Clinical symptoms:

- Vacuolar myelopathy chronic spastic
 paraparesis with sensory ataxia and urinary
 incontinence
- Sensory neuropathy
- AIDS dementia

Tx: highly active antiretroviral therapy (HAART)



Adrenoleukodystrophy - Adrenomyeloneuropathy

slowly progressive spastic paraparesis and myeloneuropathy, X-linked recessive disorder

An X-linked recessive disorder involving the ABCD1 gene.

Adults, mostly men or female carriers, experience

- slowly progressive stiffness and weakness in the legs (spastic paraparesis)
- abnormal sphincter control, neurogenic bladder, sexual dysfunction,
- polyneuropathy (numbness or painful sensations)
- pes cavus (high arches).

Diagnosis: Increase in very long chain fatty acids in plasma.

Treatment: Supportive care.

Prognosis: Most affected males lose the ability to walk unassisted by age 50.





Conclusions

- In conclusion, myeloneuropathy encompasses a group of neurological disorders characterized by the involvement of both the spinal cord (myelopathy) and peripheral nerves (neuropathy). It can present with a wide range of symptoms,
- Early recognition and intervention are essential to prevent or minimize disability



Bibliography

- Garg RK, Malhotra HS, Kumar N. Approach to a case of myeloneuropathy. Ann Indian Acad Neurol. 2016 Apr-Jun;19(2):183-7. doi: 10.4103/0972-2327.182303. PMID: 27293327; PMCID: PMC4888679.
- Goodman BP. Diagnostic approach to myeloneuropathy.
 Continuum (Minneap Minn). 2011 Aug;17(4):744-60. doi: 10.1212/01.CON.0000403793.13291.f3. PMID: 22810929.